The ELR+CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma.
Oncoimmunology
; 3: e28399, 2014.
Article
en En
| MEDLINE
| ID: mdl-25050209
ABSTRACT
The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR+CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Oncoimmunology
Año:
2014
Tipo del documento:
Article
País de afiliación:
Francia